LOUISVILLE, CO--(Marketwire - October 25, 2007) - GlobeImmune, Inc. announced today results from research on its GI-10001 Tarmogen® which is being investigated for the treatment of drug resistant chronic myelogenous leukemia (CML). Leukemia driven by the Bcr-Abl T315I mutation, known as the “gate-keeper” mutation, is resistant to treatment with imatinib mesylate or newer tyrosine kinase inhibitors including dasatinib or nilotinib. New data in mice show that treatment with GI-10001, which expresses T315I-mutated Bcr-Abl protein, triggered the immune system to selectively eliminate leukemic cells with this mutation. In addition, the Tarmogen significantly extended survival in mice after lethal challenge with cells driven by the T315I mutated Bcr-Abl.
